

**Torrent Pharma announces Q1 FY26 results**

Net profit grows 20%, driven by robust sales growth across key territories

**Ahmedabad, 28<sup>th</sup> July 2025:** Torrent Pharmaceuticals Limited (“Company”) today announced its financial results for the first quarter of FY 26.

**Revenue & profitability:**

- Revenue at Rs. 3,178 crores; grew by 11% YoY
- Op. EBITDA at Rs.1,032\* crores, up by 14% YoY
- Op. EBITDA margin at 32.5%; Gross Margin: 76%
- \*Includes acquisition related one-off expenses of Rs. 15 crores. Op. EBITDA adjusted for these one-offs is 1,047 crores, with a margin of 32.9%
- Net Profit after tax at Rs. 548 crores, up by 20% YoY.

**Performance summary:**

Results	Q1 FY26		Q1 FY25		YoY%
	Rs cr	%	Rs cr	%	
Revenues	3,178		2,859		11%
Gross profit	2,404	76%	2,165	76%	11%
Op EBITDA	1,032	32%	904	32%	14%
PAT	548	17%	457	16%	20%
R&D spend	157	5%	135	5%	16%

**India:**

- India revenues at Rs 1,811 crores were up by 11% led by outperformance in focus therapies.
- As per AIOCD secondary market data, IPM growth for the quarter was 8%.
- Torrent’s chronic business grew at 13% vs IPM growth of 9%
- Torrent has 21 brands in the Top 500 brands in IPM, with 14 brands having more than Rs.100 crores sales.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

## MEDIA RELEASE



### Brazil:

---

- Brazil revenues at Rs 218 crores, were up by 11%.
- Constant currency revenues at R\$ 143 million, were up by 16%.
- As per IQVIA, Torrent grew at 14% vs market growth of 5%.
- Growth was aided by the performance of top brands & new launches.
- Torrent has 62 products under ANVISA review.

### Germany:

---

- Germany revenues at Rs 308 crores, were up by 9%.
- Constant currency revenues at EUR 32 million, were up by 1%.
- Growth was impacted due to supply disruption at third party supplier.

### United States:

---

- US business revenues at Rs 308 crores, were up by 19%.
- Constant currency revenues at \$36 million, were up by 16% compared to same period in the previous year. Recent launches have achieved targeted market shares.

### About Torrent Pharmaceuticals Ltd:

Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. It is ranked 7<sup>th</sup> in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology.

It is a specialty-focused company with ~76% of its revenues in India from chronic & sub- chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+, scientists.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com